Drug intelligence / Profile preview

ICI 204,448

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Not Specified; Used Primarily In Laboratory Research Settings (commonly Administered Parenterally Or Topically In Animal Studies)[1][4].

Overview

ICI 204,448 is a peripherally acting κ-opioid receptor agonist developed for research purposes. It selectively activates the κ-opioid receptor (KOR) and is notable for its limited ability to cross the blood-brain barrier. This property makes it useful in studying peripheral KOR-mediated effects without significant central nervous system involvement. The compound has been investigated primarily in preclinical models for its antinociceptive (pain-relieving) properties and potential roles in modulating pruritus (itching) and other peripheral opioid-related phenomena[1][3][4][5].

Other names: ICI-204,448 hydrochloride

Targets

KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on ICI 204,448.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICI 204,448.

Explore the full profile